<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://hmg.oxfordjournals.org">
<title>Human Molecular Genetics - current issue</title>
<link>http://hmg.oxfordjournals.org</link>
<description>Human Molecular Genetics - RSS feed of current issue</description>
<prism:eIssn>1460-2083</prism:eIssn>
<prism:coverDisplayDate>15 July 2009</prism:coverDisplayDate>
<prism:publicationName>Human Molecular Genetics</prism:publicationName>
<prism:issn>0964-6906</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-a?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-b?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-c?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2523?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2532?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2543?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2555?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2567?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2575?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2584?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2599?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2609?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2622?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2632?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2643?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2656?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2670?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2683?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2693?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2700?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2711?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2719?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp244</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-a?rss=1">
<title><![CDATA[Cover Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp245</dc:identifier>
<dc:title><![CDATA[Cover Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-b?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp246</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-c?rss=1">
<title><![CDATA[Subscription Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp247</dc:identifier>
<dc:title><![CDATA[Subscription Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2523?rss=1">
<title><![CDATA[Renal injury is a third hit promoting rapid development of adult polycystic kidney disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2523?rss=1</link>
<description><![CDATA[
<p>The &lsquo;two-hit&rsquo; model is a widely accepted genetic mechanism for progressive cyst formation in autosomal dominant polycystic kidney disease. We have previously shown that adult inactivation of <I>Pkd1</I> using the <I>Mx1Cre</I><sup><I>+</I></sup> allele causes a late onset of focal cystic disease. An explanation for the delayed appearance of cysts is the requirement for an additional independent factor, or &lsquo;third hit&rsquo;. Here we show that renal injury leads to massive cystic disease in the same mouse line. Cysts are labeled with a collecting duct/tubule marker, Lectin <I>Dolichos biflorus Agglutinin</I>, which correlates with the site of Cre-mediated recombination in the collecting system. 5-Bromo-2'-deoxyuridine labeling reveals that cyst-lining epithelial cells are comprised of regenerated cells in response to renal injury. These data demonstrate, for the first time, a role for polycystin-1 in kidney injury and repair and indicate that renal injury constitutes a &lsquo;third hit&rsquo; resulting in rapid cyst formation in adulthood.</p>
]]></description>
<dc:creator><![CDATA[Takakura, A., Contrino, L., Zhou, X., Bonventre, J. V., Sun, Y., Humphreys, B. D., Zhou, J.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp147</dc:identifier>
<dc:title><![CDATA[Renal injury is a third hit promoting rapid development of adult polycystic kidney disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2531</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2523</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2532?rss=1">
<title><![CDATA[Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2532?rss=1</link>
<description><![CDATA[
<p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by large fluid-filled cysts and progressive deterioration of renal function necessitating renal replacement therapy. Previously, we generated a tamoxifen-inducible, kidney epithelium-specific <I>Pkd1</I>-deletion mouse model and showed that inactivation of the <I>Pkd1</I> gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Therefore, we hypothesized that injury-induced tubular epithelial cell proliferation may accelerate cyst formation in the kidneys of adult <I>Pkd1</I>-deletion mice. Mice were treated with the nephrotoxicant 1,2-dichlorovinyl-cysteine (DCVC) after <I>Pkd1</I>-gene inactivation, which indeed accelerated cyst formation significantly. After the increased proliferation during tissue regeneration, proliferation decreased to basal levels in <I>Pkd1</I>-deletion mice just as in DCVC-treated controls. However, in severe cystic kidneys, 10&ndash;14 weeks after injury, proliferation increased again. This biphasic response suggests that unrestricted cell proliferation after injury is not the underlying mechanism for cyst formation. Aberrant planar cell polarity (PCP) signaling and increased canonical Wnt signaling are suggested to be involved in cyst formation. Indeed, we show here that in <I>Pkd1</I> conditional deletion mice expression of the PCP component Four-jointed (<I>Fjx1</I>) is decreased while its expression is required during tissue regeneration. In addition, we show that altered centrosome position and the activation of canonical Wnt signaling are early effects of <I>Pkd1</I>-gene disruption. This suggests that additional stimuli or events are required to trigger the process of cyst formation. We propose that during tissue repair, the integrity of the newly formed <I>Pkd1</I>-deficient cells is modified rendering them susceptible to subsequent cyst formation.</p>
]]></description>
<dc:creator><![CDATA[Happe, H., Leonhard, W. N., van der Wal, A., van de Water, B., Lantinga-van Leeuwen, I. S., Breuning, M. H., de Heer, E., Peters, D. J.M.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp190</dc:identifier>
<dc:title><![CDATA[Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2542</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2532</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2543?rss=1">
<title><![CDATA[Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2543?rss=1</link>
<description><![CDATA[
<p>The Ras/MAPK pathway is critical for human development and plays a central role in the formation and progression of most cancers. Children born with germ-line mutations in BRAF, MEK1 or MEK2 develop cardio-facio-cutaneous (CFC) syndrome, an autosomal dominant syndrome characterized by a distinctive facial appearance, heart defects, skin and hair abnormalities and mental retardation. CFC syndrome mutations in BRAF promote both kinase-activating and kinase-impaired variants. CFC syndrome has a progressive phenotype, and the availability of clinically active inhibitors of the MAPK pathway prompts the important question as to whether such inhibitors might be therapeutically effective in the treatment of CFC syndrome. To study the developmental effects of CFC mutant alleles <I>in vivo</I>, we have expressed a panel of 28 BRAF and MEK alleles in zebrafish embryos to assess the function of human disease alleles and available chemical inhibitors of this pathway. We find that both kinase-activating and kinase-impaired CFC mutant alleles promote the equivalent developmental outcome when expressed during early development and that treatment of CFC-zebrafish embryos with inhibitors of the FGF-MAPK pathway can restore normal early development. Importantly, we find a developmental window in which treatment with a MEK inhibitor can restore the normal early development of the embryo, without the additional, unwanted developmental effects of the drug.</p>
]]></description>
<dc:creator><![CDATA[Anastasaki, C., Estep, A. L., Marais, R., Rauen, K. A., Patton, E. E.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp186</dc:identifier>
<dc:title><![CDATA[Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2554</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2543</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2555?rss=1">
<title><![CDATA[Characterization of six human disease-associated inversion polymorphisms]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2555?rss=1</link>
<description><![CDATA[
<p>The human genome is a highly dynamic structure that shows a wide range of genetic polymorphic variation. Unlike other types of structural variation, little is known about inversion variants within normal individuals because such events are typically balanced and are difficult to detect and analyze by standard molecular approaches. Using sequence-based, cytogenetic and genotyping approaches, we characterized six large inversion polymorphisms that map to regions associated with genomic disorders with complex segmental duplications mapping at the breakpoints. We developed a metaphase FISH-based assay to genotype inversions and analyzed the chromosomes of 27 individuals from three HapMap populations. In this subset, we find that these inversions are less frequent or absent in Asians when compared with European and Yoruban populations. Analyzing multiple individuals from outgroup species of great apes, we show that most of these large inversion polymorphisms are specific to the human lineage with two exceptions, 17q21.31 and 8p23 inversions, which are found to be similarly polymorphic in other great ape species and where the inverted allele represents the ancestral state. Investigating linkage disequilibrium relationships with genotyped SNPs, we provide evidence that most of these inversions appear to have arisen on at least two different haplotype backgrounds. In these cases, discovery and genotyping methods based on SNPs may be confounded and molecular cytogenetics remains the only method to genotype these inversions.</p>
]]></description>
<dc:creator><![CDATA[Antonacci, F., Kidd, J. M., Marques-Bonet, T., Ventura, M., Siswara, P., Jiang, Z., Eichler, E. E.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp187</dc:identifier>
<dc:title><![CDATA[Characterization of six human disease-associated inversion polymorphisms]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2566</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2555</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2567?rss=1">
<title><![CDATA[Chromatin analysis of occluded genes]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2567?rss=1</link>
<description><![CDATA[
<p>We recently described two opposing states of transcriptional competency. One is termed &lsquo;competent&rsquo; whereby a gene is capable of responding to <I>trans</I>-acting transcription factors of the cell, such that it is active if appropriate transcriptional activators are present, though it can also be silent if activators are absent or repressors are present. The other is termed &lsquo;occluded&rsquo; whereby a gene is silenced by <I>cis</I>-acting, chromatin-based mechanisms in a manner that blocks it from responding to <I>trans</I>-acting factors, such that it is silent even when activators are present in the cellular milieu. We proposed that gene occlusion is a mechanism by which differentiated cells stably maintain their phenotypic identities. Here, we describe chromatin analysis of occluded genes. We found that DNA methylation plays a causal role in maintaining occlusion for a subset of occluded genes. We further examined a variety of other chromatin marks typically associated with transcriptional silencing, including histone variants, covalent histone modifications and chromatin-associated proteins. Surprisingly, we found that although many of these marks are robustly linked to silent genes (which include both occluded genes and genes that are competent but silent), none is linked specifically to occluded genes. Although the observation does not rule out a possible causal role of these chromatin marks in occlusion, it does suggest that these marks might be secondary effect rather than primary cause of the silent state in many genes.</p>
]]></description>
<dc:creator><![CDATA[Lee, J. H., Gaetz, J., Bugarija, B., Fernandes, C. J., Snyder, G. E., Bush, E. C., Lahn, B. T.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp188</dc:identifier>
<dc:title><![CDATA[Chromatin analysis of occluded genes]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2574</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2567</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2575?rss=1">
<title><![CDATA[Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2575?rss=1</link>
<description><![CDATA[
<p>The patho-physiological hypothesis of mental retardation caused by the deficiency of the RhoGAP Oligophrenin1 (OPHN1), relies on the well-known functions of Rho GTPases on neuronal morphology, i.e. dendritic spine structure. Here, we describe a new function of this Bin/Amphiphysin/Rvs domain containing protein in the control of clathrin-mediated endocytosis (CME). Through interactions with Src homology 3 domain containing proteins involved in CME, OPHN1 is concentrated to endocytic sites where it down-regulates the RhoA/ROCK signaling pathway and represses the inhibitory function of ROCK on endocytosis. Indeed disruption of <I>Ophn1</I> in mice reduces the endocytosis of synaptic vesicles and the post-synaptic -amino-3-hydroxy-5-methylisoazol-4-propionate (AMPA) receptor internalization, resulting in almost a complete loss of long-term depression in the hippocampus. Finally, pharmacological inhibition of this pathway by ROCK inhibitors fully rescued not only the CME deficit in OPHN1 null cells but also synaptic plasticity in the hippocampus from <I>Ophn1</I> null model. Altogether, we uncovered a new patho-physiological mechanism for intellectual disabilities associated to mutations in RhoGTPases linked genes and also opened new directions for therapeutic approaches of congenital mental retardation.</p>
]]></description>
<dc:creator><![CDATA[Khelfaoui, M., Pavlowsky, A., Powell, A. D., Valnegri, P., Cheong, K. W., Blandin, Y., Passafaro, M., Jefferys, J. G.R., Chelly, J., Billuart, P.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp189</dc:identifier>
<dc:title><![CDATA[Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2583</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2575</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2584?rss=1">
<title><![CDATA[Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2584?rss=1</link>
<description><![CDATA[
<p>Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disorder of skeletal muscle caused by mutation in dystrophin gene. Although the degradation of skeletal muscle extracellular matrix, inflammation and fibrosis are the common pathological features in DMD, the underlying mechanisms remain poorly understood. In this study, we have investigated the role and the mechanisms by which increased levels of matrix metalloproteinase-9 (MMP-9) protein causes myopathy in dystrophin-deficient mdx mice. The levels of MMP-9 but not tissue inhibitor of MMPs were drastically increased in skeletal muscle of mdx mice. Besides skeletal muscle, infiltrating macrophages were found to contribute significantly to the elevated levels of MMP-9 in dystrophic muscle. <I>In vivo</I> administration of a nuclear factor-kappa B inhibitory peptide, NBD, blocked the expression of MMP-9 in dystrophic muscle of mdx mice. Deletion of <I>Mmp9</I> gene in mdx mice improved skeletal muscle structure and functions and reduced muscle injury, inflammation and fiber necrosis. Inhibition of MMP-9 increased the levels of cytoskeletal protein &beta;-dystroglycan and neural nitric oxide synthase and reduced the amounts of caveolin-3 and transforming growth factor-&beta; in myofibers of mdx mice. Genetic ablation of MMP-9 significantly augmented the skeletal muscle regeneration in mdx mice. Finally, pharmacological inhibition of MMP-9 activity also ameliorated skeletal muscle pathogenesis and enhanced myofiber regeneration in mdx mice. Collectively, our study suggests that the increased production of MMP-9 exacerbates dystrophinopathy and MMP-9 represents as one of the most promising therapeutic targets for the prevention of disease progression in DMD.</p>
]]></description>
<dc:creator><![CDATA[Li, H., Mittal, A., Makonchuk, D. Y., Bhatnagar, S., Kumar, A.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp191</dc:identifier>
<dc:title><![CDATA[Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2598</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2584</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2599?rss=1">
<title><![CDATA[The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2599?rss=1</link>
<description><![CDATA[
<p>It has long been recognized that E-cadherin dysfunction is a major cause of epithelial cell invasion. However, very little is known about the post-transcriptional modifications of E-cadherin and its role in E-cadherin mediated tumor progression. N-acetylglucosaminyltransferase III (GnT-III) catalyzes the formation of a bisecting GlcNAc structure in N-glycans, and has been pointed as a metastasis suppressor. N-acetylglucosaminyltransferase V (GnT-V) catalyzes the addition of &beta;1,6 GlcNAc branching of N-glycans, and has been associated to increase metastasis. The regulatory mechanism between E-cadherin expression and the remodeling of its oligosaccharides structures by GnT-III and GnT-V were explored in this study. We have demonstrated that wild-type E-cadherin regulates <I>MGAT3</I> gene transcription resulting in increased GnT-III expression. We also showed that GnT-III and GnT-V competitively modified E-cadherin N-glycans. The GnT-III knockdown cells revealed a membrane de-localization of E-cadherin leading to its cytoplasmic accumulation. Further, the GnT-III knockdown cells also caused modifications of E-cadherin N-glycans catalyzed by GnT-III and GnT-V. Altogether our results have clarified the existence of a bidirectional crosstalk between E-cadherin and GnT-III/GnT-V that was, for the first time, reproduced in an <I>in vivo</I> model. This study opens new insights into the post-transcriptional modifications of E-cadherin in its biological function, in a tumor context.</p>
]]></description>
<dc:creator><![CDATA[Pinho, S. S., Reis, C. A., Paredes, J., Magalhaes, A. M., Ferreira, A. C., Figueiredo, J., Xiaogang, W., Carneiro, F., Gartner, F., Seruca, R.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp194</dc:identifier>
<dc:title><![CDATA[The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2608</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2599</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2609?rss=1">
<title><![CDATA[The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2609?rss=1</link>
<description><![CDATA[
<p>Mutations in fibroblast growth factor receptors (FGFRs) cause human birth defect syndromes and are associated with a variety of cancers. Although forced expression of mutant activated FGFRs has been shown to oncogenically transform some immortal cell types, their activity in primary cells remains unclear. Here, we show that birth defect and cancer-associated FGFR2 mutants promote DNA-damage signaling and p53-dependent senescence in primary mouse and human cells. Senescence promoted by FGFR mutants was associated with downregulation of c-Myc and forced expression of c-Myc facilitated senescence escape. Whereas c-Myc expression facilitated senescence bypass, mutant FGFR2 signaling suppressed c-Myc-dependent apoptosis and led to oncogenic transformation. Cells transformed by coexpression of a constitutively activated FGFR2 mutant plus c-Myc appeared to be become highly addicted to FGFR-dependent prosurvival activities, as small molecule inhibition of FGFR signaling resulted in robust p53-dependent apoptosis. Our data suggest that senescence-promoting activities of mutant FGFRs may normally limit their oncogenic potential and may be relevant to their ability to disrupt morphogenesis and cause birth defects. Our results also raise the possibility that cancers originating through a combination of constitutive FGFR activation and deregulated Myc expression may be particularly sensitive to small molecule inhibitors of FGF receptors.</p>
]]></description>
<dc:creator><![CDATA[Ota, S., Zhou, Z.-Q., Link, J. M., Hurlin, P. J.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp195</dc:identifier>
<dc:title><![CDATA[The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2621</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2609</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2622?rss=1">
<title><![CDATA[Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2622?rss=1</link>
<description><![CDATA[
<p>The majority of the Lafora's disease (LD) is caused by defect in the <I>EPM2A</I> gene, including missense and nonsense mutations and deletions. These defects mainly occur in the carbohydrate-binding domain, and how these mutations cause neuronal defects is under active investigation. Here, we report that the mutant proteins encoded by all missense mutations and most deletions tested are unstable, insoluble and ubiquitinated, and are accumulated in aggresome-like structures. The effect of apparent &lsquo;gain-of-function&rsquo; mutations can be corrected by co-transfection of wild-type <I>EPM2A</I> cDNA, which is consistent with the recessive nature of these mutations in LD patients. In a neuronal cell line, these mutant aggregates exacerbate endoplasm reticulum (ER) stress and make the cells susceptible to the apoptosis induced by ER stressor, thapsigargin. The chemical chaperon, 4-phenylbutyrate, increased the mutant solubility, reduced the ER stress and dulled the sensitivity of mutant neuronal cells to apoptosis induced by thapsigargin and the mutant laforin proteins. The increased sensitivity to ER stress-induced apoptosis may contribute to LD pathogenesis.</p>
]]></description>
<dc:creator><![CDATA[Liu, Y., Wang, Y., Wu, C., Liu, Y., Zheng, P.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp196</dc:identifier>
<dc:title><![CDATA[Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2631</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2622</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2632?rss=1">
<title><![CDATA[Integration of IRF6 and Jagged2 signalling is essential for controlling palatal adhesion and fusion competence]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2632?rss=1</link>
<description><![CDATA[
<p>In mammals, adhesion and fusion of the palatal shelves are essential mechanisms during the development of the secondary palate; failure of these processes leads to the congenital anomaly, cleft palate. The mechanisms that prevent pathological adhesion between the oral and palatal epithelia while permitting adhesion and subsequent fusion of the palatal shelves via their medial edge epithelia remain obscure. In humans, mutations in the transcription factor interferon regulatory factor 6 (IRF6) underlie Van der Woude syndrome and popliteal pterygium syndrome. Recently, we have demonstrated that mice homozygous for a mutation in <I>Irf6</I> exhibit abnormalities of epithelial differentiation that results in cleft palate as a consequence of adhesion between the palatal shelves and the tongue. In the current paper, we demonstrate that <I>Irf6</I> is essential for oral epithelial differentiation and that IRF6 and the Notch ligand Jagged2 function in convergent molecular pathways during this process. We further demonstrate that IRF6 plays a key role in the formation and maintenance of the oral periderm, spatio-temporal regulation of which is essential for ensuring appropriate palatal adhesion.</p>
]]></description>
<dc:creator><![CDATA[Richardson, R. J., Dixon, J., Jiang, R., Dixon, M. J.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp201</dc:identifier>
<dc:title><![CDATA[Integration of IRF6 and Jagged2 signalling is essential for controlling palatal adhesion and fusion competence]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2642</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2632</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2643?rss=1">
<title><![CDATA[X-linked cataract and Nance-Horan syndrome are allelic disorders]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2643?rss=1</link>
<description><![CDATA[
<p>Nance-Horan syndrome (NHS) is an X-linked developmental disorder characterized by congenital cataract, dental anomalies, facial dysmorphism and, in some cases, mental retardation. Protein truncation mutations in a novel gene (<I>NHS</I>) have been identified in patients with this syndrome. We previously mapped X-linked congenital cataract (CXN) in one family to an interval on chromosome Xp22.13 which encompasses the <I>NHS</I> locus; however, no mutations were identified in the <I>NHS</I> gene. In this study, we show that NHS and X-linked cataract are allelic diseases. Two CXN families, which were negative for mutations in the <I>NHS</I> gene, were further analysed using array comparative genomic hybridization. CXN was found to be caused by novel copy number variations: a complex duplication&ndash;triplication re-arrangement and an intragenic deletion, predicted to result in altered transcriptional regulation of the <I>NHS</I> gene. Furthermore, we also describe the clinical and molecular analysis of seven families diagnosed with NHS, identifying four novel protein truncation mutations and a novel large deletion encompassing the majority of the <I>NHS</I> gene, all leading to no functional protein. We therefore show that different mechanisms, aberrant transcription of the <I>NHS</I> gene or no functional NHS protein, lead to different diseases. Our data highlight the importance of copy number variation and non-recurrent re-arrangements leading to different severity of disease and describe the potential mechanisms involved.</p>
]]></description>
<dc:creator><![CDATA[Coccia, M., Brooks, S. P., Webb, T. R., Christodoulou, K., Wozniak, I. O., Murday, V., Balicki, M., Yee, H. A., Wangensteen, T., Riise, R., Saggar, A. K., Park, S.-M., Kanuga, N., Francis, P. J., Maher, E. R., Moore, A. T., Russell-Eggitt, I. M., Hardcastle, A. J.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp206</dc:identifier>
<dc:title><![CDATA[X-linked cataract and Nance-Horan syndrome are allelic disorders]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2655</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2643</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2656?rss=1">
<title><![CDATA[Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2656?rss=1</link>
<description><![CDATA[
<p>Ataxia telangiectasia (AT) is a chromosome instability (CIN) neurological syndrome arising from DNA damage response defects due to <I>ATM</I> gene mutations. The hallmark of AT is progressive cerebellar degeneration. However, the intrinsic cause of the neurodegeneration remains poorly understood. To highlight the relationship between CIN and neurodegeneration in AT, we monitored aneuploidy and interphase chromosome breaks (chromosomal biomarkers of genomic instability) in the normal and diseased brain. We observed a 2&ndash;3-fold increase of stochastic aneuploidy affecting different chromosomes in the cerebellum and the cerebrum of the AT brain. The global aneuploidization of the brain is, therefore, a new genetic phenomenon featuring AT. Degenerating cerebellum in AT was remarkably featured by a dramatic 5&ndash;20-fold increase of non-random DNA double-strand breaks and aneuploidy affecting chromosomes 14 and, to a lesser extend, chromosomes 7 and X. Novel recurrent chromosome hot spots associated with cerebellar degeneration were mapped within 14q12. <I>In silico</I> analysis has revealed that this genomic region contains two candidate genes (<I>FOXG1B</I> and <I>NOVA1</I>). The existence of non-random breaks disrupting specific chromosomal loci in neural cells with DNA repair deficiency supports the hypothesis that neuronal genome may undergo programmed somatic rearrangements. Investigating chromosome integrity in neural cells, we provide the first evidence that increased CIN can result into neurodegeneration, whereas it is generally assumed to be associated with cancer. Our data suggest that mosaic instability of somatic genome in cells of the central nervous system is more significant genetic factor predisposing to the brain pathology than previously recognized.</p>
]]></description>
<dc:creator><![CDATA[Iourov, I. Y., Vorsanova, S. G., Liehr, T., Kolotii, A. D., Yurov, Y. B.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp207</dc:identifier>
<dc:title><![CDATA[Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2669</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2656</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2670?rss=1">
<title><![CDATA[Elucidation of separate, but collaborative functions of the rRNA methyltransferase-related human mitochondrial transcription factors B1 and B2 in mitochondrial biogenesis reveals new insight into maternally inherited deafness]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2670?rss=1</link>
<description><![CDATA[
<p>Mitochondrial biogenesis is controlled by signaling networks that relay information to and from the organelles. However, key mitochondrial factors that mediate such pathways and how they contribute to human disease are not understood fully. Here we demonstrate that the rRNA methyltransferase-related human mitochondrial transcription factors B1 and B2 are key downstream effectors of mitochondrial biogenesis that perform unique, yet cooperative functions. The primary function of h-mtTFB2 is mtDNA transcription and maintenance, which is independent of its rRNA methyltransferase activity, while that of h-mtTFB1 is mitochondrial 12S rRNA methylation needed for normal mitochondrial translation, metabolism and cell growth. Over-expression of h-mtTFB1 causes 12S rRNA hypermethylation, aberrant mitochondrial biogenesis and increased sorbitol-induced cell death. These phenotypes are recapitulated in cells harboring the pathogenic A1555G mtDNA mutation, implicating a deleterious rRNA methylation-dependent retrograde signal in maternally inherited deafness pathology and shedding significant insight into how h-mtTFB1 acts as a nuclear modifier of this disease.</p>
]]></description>
<dc:creator><![CDATA[Cotney, J., McKay, S. E., Shadel, G. S.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp208</dc:identifier>
<dc:title><![CDATA[Elucidation of separate, but collaborative functions of the rRNA methyltransferase-related human mitochondrial transcription factors B1 and B2 in mitochondrial biogenesis reveals new insight into maternally inherited deafness]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2682</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2670</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2683?rss=1">
<title><![CDATA[Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2683?rss=1</link>
<description><![CDATA[
<p>The prevalence of CD36 deficiency in East Asian and African populations suggests that the causal variants are under selection by severe malaria. Previous analysis of data from the International HapMap Project indicated that a <I>CD36</I> haplotype bearing a nonsense mutation (T1264G; rs3211938) had undergone recent positive selection in the Yoruba of Nigeria. To investigate the global distribution of this putative selection event, we genotyped T1264G in 3420 individuals from 66 populations. We confirmed the high frequency of 1264G in the Yoruba (26%). However, the 1264G allele is less common in other African populations and absent from all non-African populations without recent African admixture. Using long-range linkage disequilibrium, we studied two West African groups in depth. Evidence for recent positive selection at the locus was demonstrable in the Yoruba, although not in Gambians. We screened 70 variants from across <I>CD36</I> for an association with severe malaria phenotypes, employing a case&ndash;control study of 1350 subjects and a family study of 1288 parent&ndash;offspring trios. No marker was significantly associated with severe malaria. We focused on T1264G, genotyping 10 922 samples from four African populations. The nonsense allele was not associated with severe malaria (pooled allelic odds ratio 1.0; 95% confidence interval 0.89&ndash;1.12; <I>P</I> = 0.98). These results suggest a range of possible explanations including the existence of alternative selection pressures on <I>CD36</I>, co-evolution between host and parasite or confounding caused by allelic heterogeneity of CD36 deficiency.</p>
]]></description>
<dc:creator><![CDATA[Fry, A. E., Ghansa, A., Small, K. S., Palma, A., Auburn, S., Diakite, M., Green, A., Campino, S., Teo, Y. Y., Clark, T. G., Jeffreys, A. E., Wilson, J., Jallow, M., Sisay-Joof, F., Pinder, M., Griffiths, M. J., Peshu, N., Williams, T. N., Newton, C. R., Marsh, K., Molyneux, M. E., Taylor, T. E., Koram, K. A., Oduro, A. R., Rogers, W. O., Rockett, K. A., Sabeti, P. C., Kwiatkowski, D. P.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp192</dc:identifier>
<dc:title><![CDATA[Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2692</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2683</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2693?rss=1">
<title><![CDATA[Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2693?rss=1</link>
<description><![CDATA[
<p>The most consistent finding derived from the WTCCC GWAS for rheumatoid arthritis (RA) was association to a SNP at 6q23. We performed a fine-mapping of the region in order to search the 6q23 region for additional disease variants. 3962 RA patients and 3531 healthy controls were included in the study. We found 18 SNPs associated with RA. The SNP showing the strongest association was rs6920220 [<I>P</I> = 2.6 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup>, OR (95% CI) 1.22 (1.13&ndash;1.33)]. The next most strongly associated SNP was rs13207033 [<I>P</I> = 0.0001, OR (95% CI) 0.86 (0.8&ndash;0.93)] which was perfectly correlated with rs10499194, a SNP previously associated with RA in a US/European series. Additionally, we found a number of new potential RA markers, including rs5029937, located in the intron 2 of <I>TNFAIP3</I>. Of the 18 associated SNPs, three polymorphisms, rs6920220, rs13207033 and rs5029937, remained significant after conditional logistic regression analysis. The combination of the carriage of both risk alleles of rs6920220 and rs5029937 together with the absence of the protective allele of rs13207033 was strongly associated with RA when compared with carriage of none [OR of 1.86 (95% CI) (1.51&ndash;2.29)]. This equates to an effect size of 1.50 (95% CI 1.21&ndash;1.85) compared with controls and is higher than that obtained for any SNP individually. This is the first study to show that the confirmed loci from the GWA studies, that confer only a modest effect size, could harbour a significantly greater effect once the effect of additional risk variants are accounted for.</p>
]]></description>
<dc:creator><![CDATA[Orozco, G., Hinks, A., Eyre, S., Ke, X., Gibbons, L. J., Bowes, J., Flynn, E., Martin, P., Wellcome Trust Case Control Consortium, YEAR consortium, Wilson, A. G., Bax, D. E., Morgan, A. W., Emery, P., Steer, S., Hocking, L., Reid, D. M., Wordsworth, P., Harrison, P., Thomson, W., Barton, A., Worthington, J.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp193</dc:identifier>
<dc:title><![CDATA[Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2699</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2693</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2700?rss=1">
<title><![CDATA[Genome-wide association meta-analysis for total serum bilirubin levels]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2700?rss=1</link>
<description><![CDATA[
<p>Variation in serum bilirubin is associated with altered cardiovascular disease risk and drug metabolism. We aimed to identify genetic contributors to variability in serum bilirubin levels by combining results from three genome-wide association studies (Framingham heart study, <I>n</I> = 3424; Rotterdam study, <I>n</I> = 3847; Age, Gene, Environment and Susceptibility-Reykjavik, <I>n</I> = 2193). Meta-analysis showed strong replication for a genetic influence on serum bilirubin levels of the <I>UGT1A1</I> locus (<I>P</I> &lt; 5 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;324</sup>) and a 12p12.2 locus. The peak signal in the 12p12.2 region was a non-synonymous SNP in <I>SLCO1B1</I> (rs4149056, <I>P</I> = 6.7 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;13</sup>), which gives rise to a valine to alanine amino acid change leading to reduced activity for a hepatic transporter with known affinity for bilirubin. There were also suggestive associations with several other loci. The top variants in <I>UGT1A1</I> and <I>SLCO1B1</I> explain ~18.0 and ~1.0% of the variation in total serum bilirubin levels, respectively. In a conditional analysis adjusted for individual genotypes for the top <I>UGT1A1</I> variant, the top <I>SLCO1B1</I> variant remained highly significant (<I>P</I> = 7.3 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;13</sup>), but no other variants achieved genome-wide significance. In one of the largest genetic studies of bilirubin to date (<I>n</I> = 9464), we confirm the substantial genetic influence of <I>UGT1A1</I> variants, consistent with past linkage and association studies, and additionally provide strong evidence of a role for allelic variation in <I>SLCO1B1</I>. Given the involvement of bilirubin in a number of physiological and disease processes, and the roles for <I>UGT1A1</I> and <I>SLCO1B1</I> in drug metabolism, these genetic findings have potential clinical importance. In analyses for association with gallbladder disease or gallstones, top bilirubin SNPs in <I>UGT1A1</I> and <I>SLCO1B1</I> were not associated.</p>
]]></description>
<dc:creator><![CDATA[Johnson, A. D., Kavousi, M., Smith, A. V., Chen, M.-H., Dehghan, A., Aspelund, T., Lin, J.-P., van Duijn, C. M., Harris, T. B., Cupples, L. A., Uitterlinden, A. G., Launer, L., Hofman, A., Rivadeneira, F., Stricker, B., Yang, Q., O'Donnell, C. J., Gudnason, V., Witteman, J. C.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp202</dc:identifier>
<dc:title><![CDATA[Genome-wide association meta-analysis for total serum bilirubin levels]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2710</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2700</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2711?rss=1">
<title><![CDATA[Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2711?rss=1</link>
<description><![CDATA[
<p>Bilirubin, resulting largely from the turnover of hemoglobin, is found in the plasma in two main forms: unconjugated or conjugated with glucuronic acid. Unconjugated bilirubin is transported into hepatocytes. There, it is glucuronidated by <I>UGT1A1</I> and secreted into the bile canaliculi. We report a genome wide association scan in 4300 Sardinian individuals for total serum bilirubin levels. In addition to the two known loci previously involved in the regulation of bilirubin levels, <I>UGT1A1</I> (<I>P</I> = 6.2 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;62</sup>) and <I>G6PD</I> (<I>P</I> = 2.5 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>), we observed a strong association on chromosome 12 within the <I>SLCO1B3</I> gene (<I>P</I> = 3.9 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;9</sup>). Our findings were replicated in an independent sample of 1860 Sardinians and in 832 subjects from the Old Order Amish (combined <I>P</I> &lt; 5 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;14</sup>). We also show that <I>SLC01B3</I> variants contribute to idiopathic mild unconjugated hyperbilirubinemia. Thus, <I>SLC01B3</I> appears to be involved in the regulation of serum bilirubin levels in healthy individuals and in some bilirubin-related disorders that are only partially explained by other known gene variants.</p>
]]></description>
<dc:creator><![CDATA[Sanna, S., Busonero, F., Maschio, A., McArdle, P. F., Usala, G., Dei, M., Lai, S., Mulas, A., Piras, M. G., Perseu, L., Masala, M., Marongiu, M., Crisponi, L., Naitza, S., Galanello, R., Abecasis, G. R., Shuldiner, A. R., Schlessinger, D., Cao, A., Uda, M.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp203</dc:identifier>
<dc:title><![CDATA[Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2718</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2711</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/14/2719?rss=1">
<title><![CDATA[The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/14/2719?rss=1</link>
<description><![CDATA[
<p>Association studies, as well as the initial translocation family study, identified the gene <I>Disrupted-In-Schizophrenia-1</I> (<I>DISC1</I>) as a risk factor for schizophrenia. <I>DISC1</I> encodes a multifunctional scaffold protein involved in neurodevelopmental processes implicated in the etiology of schizophrenia. The present study explores the contribution of the <I>DISC</I> locus to schizophrenia using three different approaches: (i) systematic association mapping aimed at detecting <I>DISC</I> risk variants in a schizophrenia sample from a central European population (556 SNPs, <I>n</I> = 1621 individuals). In this homogenous sample, a circumscribed <I>DISC1</I> interval in intron 9 was significantly associated with schizophrenia in females (<I>P</I> = 4 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>) and contributed most strongly to early-onset cases (<I>P</I> = 9 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>). The odds ratios (ORs) were in the range of 1.46&ndash;1.88. (ii) The same sample was used to test for the locus-specific SNP&ndash;SNP interaction most recently associated with schizophrenia. Our results confirm the SNP interplay effect between rs1538979 and rs821633 that significantly conferred disease risk in male patients with schizophrenia (<I>P</I> = 0.016, OR 1.57). (iii) In order to detect additional schizophrenia variants, a meta-analysis was performed using nine schizophrenia samples from different European populations (50 SNPs, <I>n</I> = 10 064 individuals maximum, <I>n</I> = 3694 minimum). We found evidence for a common schizophrenia risk interval within <I>DISC1</I> intron 4&ndash;6 (<I>P</I> = 0.002, OR 1.27). The findings point to a complex association between schizophrenia and <I>DISC</I>, including the presence of different risk loci and SNP interplay effects. Furthermore, our phenotype&ndash;genotype results&mdash;including the consideration of sex-specific effects&mdash;highlight the value of homogenous samples in mapping risk genes for schizophrenia in general, and at the <I>DISC</I> locus in particular.</p>
]]></description>
<dc:creator><![CDATA[Schumacher, J., Laje, G., Jamra, R. A., Becker, T., Muhleisen, T. W., Vasilescu, C., Mattheisen, M., Herms, S., Hoffmann, P., Hillmer, A. M., Georgi, A., Herold, C., Schulze, T. G., Propping, P., Rietschel, M., McMahon, F. J., Nothen, M. M., Cichon, S.]]></dc:creator>
<dc:date>2009-06-23</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp204</dc:identifier>
<dc:title><![CDATA[The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>14</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>2727</prism:endingPage>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:startingPage>2719</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

</rdf:RDF>